Tyra Biosciences reported cash from operations of -$31.08M and free cash flow of -$31.14M for the quarter ended Jun 2026, down 31.2% year over year. This cash flow statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||
| Net Income | -6.64M | -9.93M | -14.83M | -15.10M | -12.52M | -12.89M | -11.88M | -13.29M | -21.15M | -22.83M | -18.19M | -18.70M | -24.02M | -25.57M | -28.15M | -28.10M | -29.87M | -33.83M | -39.30M | -45.56M | ||||
| Share-based Compensation | 2.59M | 1.65M | 24.50M | 4.51M | 5.95M | 2.91M | 6.13M | 6.04M | 8.11M | 4.19M | 8.35M | 8.60M | 10.75M | 6.70M | 10.17M | 10.41M | 71.50M | 7.63M | 74.40M | 14.41M | ||||
| Cash from Operations | -5.58M | -9.03M | -8.93M | -17.17M | -12.21M | -11.98M | -9.85M | -9.62M | -17.14M | -13.53M | -22.03M | -10.26M | -17.90M | -19.59M | -25.46M | -23.68M | -22.38M | -23.62M | -32.57M | -31.08M | ||||
| Depreciation, Depletion & Amortization | ||||||||||||||||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.04M | 0.05M | 0.06M | 0.07M | 0.08M | 0.08M | 0.08M | 0.09M | 0.08M | 0.10M | 0.12M | 0.13M | 0.13M | 0.14M | 0.14M | 0.14M | 0.13M | 0.13M | 0.14M | 0.14M | ||||
| Change in Working Capital | ||||||||||||||||||||||||
| Change in Accured Expenses | 1.23M | 0.10M | 1.56M | 0.54M | 0.05M | 0.21M | -2.02M | 1.67M | 4.64M | 5.08M | -6.91M | 1.94M | 2.01M | 2.21M | -0.36M | -0.49M | 2.07M | 2.16M | 1.20M | 5.32M | ||||
| Investing Activities | ||||||||||||||||||||||||
| Capital Expenditures | 0.26M | 0.10M | 0.24M | 0.25M | 0.05M | 0.02M | 0.04M | 0.04M | 0.08M | 0.60M | 0.14M | 0.47M | 0.05M | 0.01M | 0.01M | 0.03M | 0.04M | 0.06M | 0.09M | 0.07M | ||||
| Change in Acquisitions & Divestments | 30.00M | 32.88M | 58.00M | 45.00M | 38.91M | 41.00M | 50.41M | 43.54M | 42.05M | 40.00M | ||||||||||||||
| Cash from Investing Activities | -0.24M | -0.10M | -0.24M | -0.25M | -0.05M | -0.02M | -0.04M | -0.04M | -0.08M | -144.44M | 18.07M | -144.99M | 21.56M | 6.96M | 32.03M | 20.87M | -14.81M | 34.38M | -120.24M | 17.85M | ||||
| Financing Activities | ||||||||||||||||||||||||
| Other financing activities | -1.51M | |||||||||||||||||||||||
| Change in Capital Stock | ||||||||||||||||||||||||
| Net Shares Issued and Repurchased | 3.29M | 0.19M | 0.51M | 0.54M | 0.40M | 0.17M | 0.29M | 0.43M | 0.97M | 0.28M | ||||||||||||||
| Net Equity Issued and Repurchased | 147.85M | |||||||||||||||||||||||
| Misc. | ||||||||||||||||||||||||
| Cash from Financing Activities | 183.44M | -1.51M | 0.24M | 0.03M | 0.36M | 0.00M | 0.38M | 0.37M | 0.47M | 0.32M | 200.31M | 0.37M | 0.74M | 0.71M | 2.19M | 0.58M | 0.65M | 4.68M | 160.38M | 2.10M | ||||
| Change in Cash | 177.62M | -10.64M | -8.93M | -17.39M | -11.90M | -12.00M | -9.51M | -9.29M | -16.76M | -157.65M | 196.36M | -154.88M | 4.40M | -11.93M | 8.76M | -2.23M | -36.54M | 15.44M | 7.57M | -11.12M | ||||
| Free Cash Flow | -5.83M | -9.13M | -9.16M | -17.42M | -12.26M | -12.00M | -9.89M | -9.66M | -17.23M | -14.13M | -22.16M | -10.73M | -17.95M | -19.60M | -25.47M | -23.71M | -22.42M | -23.68M | -32.66M | -31.14M | ||||
| Net Cash Flow | 177.62M | -10.64M | -8.93M | -17.39M | -11.90M | -12.00M | -9.51M | -9.29M | -16.76M | -157.65M | 196.36M | -154.88M | 4.40M | -11.93M | 8.76M | -2.23M | -36.54M | 15.44M | 7.57M | -11.12M |